TY - JOUR
T1 - Clinical subgroups in bilateral meniere disease
AU - Frejo, Lidia
AU - Soto-Varela, Andres
AU - Santos-Perez, Sofía
AU - Aran, Ismael
AU - Batuecas-Caletrio, Angel
AU - Perez-Guillen, Vanesa
AU - Perez-Garrigues, Herminio
AU - Fraile, Jesus
AU - Martin-Sanz, Eduardo
AU - Tapia, Maria C.
AU - Trinidad, Gabriel
AU - García-Arumi, Ana María
AU - González-Aguado, Rocío
AU - Espinosa-Sanchez, Juan M.
AU - Marques, Pedro
AU - Perez, Paz
AU - Benitez, Jesus
AU - Lopez-Escamez, Jose A.
AU - Amor-Dorado, Juan Carlos
AU - Huarte, Raquel Manrique
AU - Perez-Fernandez, Nicolas
AU - Sanz, Ricardo
AU - Dominguez, Manuel Oliva
AU - Teggi, Roberto
AU - On Behalf of the Meniere's Disease Consortium (MeDiC)
PY - 2016/10/24
Y1 - 2016/10/24
N2 - Meniere disease (MD) is a heterogeneous clinical condition characterized by sensorineural hearing loss, episodic vestibular symptoms, and tinnitus associated with several comorbidities, such as migraine or autoimmune disorders (AD). The frequency of bilateral involvement may range from 5 to 50%, and it depends on the duration of the disease. We have performed a two-step cluster analysis in 398 patients with bilateral MD (BMD) to identify the best predictors to define clinical subgroups with a potential different etiology to improve the phenotyping of BMD and to develop new treatments. We have defined five clinical variants in BMD. Group 1 is the most frequently found, includes 46% of patients, and is defined by metachronic hearing loss without migraine and without AD. Group 2 is found in 17% of patients, and it is defined by synchronic hearing loss without migraine or AD. Group 3, with 13% of patients, is characterized by familial MD, while group 4, that includes 12% of patients, is associated by the presence of migraine in all cases. Group 5 is found in 11% of patients and is defined by AD. This approach can be helpful in selecting patients for genetic and clinical research. However, further studies will be required to improve the phenotyping in these clinical variants for a better understanding of the diverse etiological factors contributing to BMD.
AB - Meniere disease (MD) is a heterogeneous clinical condition characterized by sensorineural hearing loss, episodic vestibular symptoms, and tinnitus associated with several comorbidities, such as migraine or autoimmune disorders (AD). The frequency of bilateral involvement may range from 5 to 50%, and it depends on the duration of the disease. We have performed a two-step cluster analysis in 398 patients with bilateral MD (BMD) to identify the best predictors to define clinical subgroups with a potential different etiology to improve the phenotyping of BMD and to develop new treatments. We have defined five clinical variants in BMD. Group 1 is the most frequently found, includes 46% of patients, and is defined by metachronic hearing loss without migraine and without AD. Group 2 is found in 17% of patients, and it is defined by synchronic hearing loss without migraine or AD. Group 3, with 13% of patients, is characterized by familial MD, while group 4, that includes 12% of patients, is associated by the presence of migraine in all cases. Group 5 is found in 11% of patients and is defined by AD. This approach can be helpful in selecting patients for genetic and clinical research. However, further studies will be required to improve the phenotyping in these clinical variants for a better understanding of the diverse etiological factors contributing to BMD.
KW - Autoimmune disorders
KW - Cluster analysis
KW - Hearing loss
KW - Inner ear
KW - Meniere's disease
KW - Migraine
KW - Tinnitus
KW - Vestibular disorders
UR - http://www.scopus.com/inward/record.url?scp=84995475713&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84995475713&partnerID=8YFLogxK
U2 - 10.3389/fneur.2016.00182
DO - 10.3389/fneur.2016.00182
M3 - Article
AN - SCOPUS:84995475713
SN - 1664-2295
VL - 7
JO - Frontiers in Neurology
JF - Frontiers in Neurology
IS - OCT
M1 - 182
ER -